血塞通软胶囊对急性腔隙性梗死合并脑微出血患者临床疗效的评价

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (5): 574-579.

血塞通软胶囊对急性腔隙性梗死合并脑微出血患者临床疗效的评价

王美华，翁秋燕，查芹，牛艳芳

宁波大学医学院附属医院神经内科，宁波 315000，浙江

收稿日期:2016-12-05 修回日期:2017-01-08 出版日期:2017-05-26 发布日期:2017-05-27
通讯作者: 查芹，女，主任医师，研究方向：痴呆、脑血管疾病。 Tel:18258607184 E-mail:603782639@qq.com
作者简介:王美华，女，本科，主治医师，研究方向：肌张力障碍、脑血管病。 Tel:18258607184 E-mail:982044@163.com
基金资助:
宁波市科技惠民项目（2015C50007）;浙江省医药卫生科技项目计划（2015KYB341）

Effect of Xuesaitong soft capsule on acute lacunar cerebral infarction combined with cerebral microbleeds

WANG Meihua, WENG Qiuyan, ZHA Qin, NIU Yanfang

Second Department of Neurology, Affiliated Hospital of Medical College of Ningbo University, Ningbo 315000, Zhejiang, China

Received:2016-12-05 Revised:2017-01-08 Online:2017-05-26 Published:2017-05-27

摘要/Abstract

摘要：

目的: 观察血塞通软胶囊治疗急性腔隙性梗死合并脑微出血的临床疗效及对患者血清中钙黏蛋白S100B、可溶性糖基化终产物受体（sRAGE）水平的影响。方法: 本院就诊的86例急性腔隙性梗死合并脑微出血患者随机分为对照组和试验组，每组43例。对照组患者给予基础治疗，试验组患者在此基础上加用血塞通软胶囊，2粒/次，每日3次。两组疗程均为8周。比较2组患者的临床疗效、神经功能缺损评分、NIHSS评分和MRS评分变化、血清中S100B、sRAGE变化水平及不良反应。结果: 试验组患者治疗总有效率为90.70%，显著高于对照组的74.42%（P<0.05）。试验组CSS评分、NIHSS评分治疗后显著低于对照组（P<0.01）；试验组患者血清中S100B表达水平显著低于对照组（P<0.05），sRAGE水平显著高于对照组（P<0.05）；治疗过程中未发现明显不良反应发生。结论: 血塞通软胶囊对急性腔隙性梗死合并脑微出血临床效果显著，值得临床推广。

关键词: 脑微出血, 血塞通软胶囊, 腔隙性脑梗死, 钙黏蛋白S100B, 可溶性糖基化终产物受体

Abstract:

AIM: To evaluate the clinical efficacy of Xuesaitong soft capsule in the treatment of acute lacunar cerebral infarction combined with cerebral microbleeds and its influence on S100B and soluble receptor for advanced glycation end products (sRAGE) in serum. METHODS: Eighty-six patients with acute lacunar cerebral infarction and cerebral microbleeds were randomly divided into control group and treatment group, 43 cases in each group. Control group received basic treatment. Treatment group were treated with Xuesaitong soft capsule additionally for a course of 8 weeks. Clinical efficacy, scores of CSS, NIHSS and MRS, levels of S100B and sRAGE in serum and adverse reactions were compared between the two groups. RESULTS:The effective rate in treatment group was 90.70%, significantly higher than 74.42% in control group (P<0.05). After treatment, scores of CSS and NIHSS in treatment group were significantly lower than those in control group (P<0.01). The level of S100B in serum in treatment group was significantly lower than that in control group (P<0.05), and the level of sRAGE in serum in treatment group was significantly higher than that in control group (P<0.05). During treatment, no significant adverse reactions were exhibited. CONCLUSION: Xuesaitong soft capsule has obvious curative effect on acute lacunar cerebral infarction combined with cerebral microbleeds, which is referential for clinical application.

Key words: cerebral microbleeds, xuesaitong soft capsule, acute lacunar cerebral infarction, S100B, soluble receptor for advanced glycation end products

中图分类号:

R743

王美华，翁秋燕，查芹，牛艳芳. 血塞通软胶囊对急性腔隙性梗死合并脑微出血患者临床疗效的评价[J]. 中国临床药理学与治疗学, 2017, 22(5): 574-579.

WANG Meihua, WENG Qiuyan, ZHA Qin, NIU Yanfang. Effect of Xuesaitong soft capsule on acute lacunar cerebral infarction combined with cerebral microbleeds[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 574-579.

参考文献

［1］Greenberg SM, Vemooij MW, Cordonnier C, et al. Cerebral microbleeds:a guide to detection and interpretation［J］.Lancet Neurol,2009,8:165-174.
［2］肖露露, 杜娟, 朱武生. 脑微出血预测颅内出血的研究进展［J］.中国脑血管杂志,2012,9:600-603.
［3］Guo LF, Wang G, Zhu XY, et al. Comparison of ESWAN, SWI-SPGR, and 2D T2*-Weighted GRE sequence for depicting cerebral microbleeds［J］.Clin Neuroradiol,2013,23(2): 121-127.
［4］Charidimou A, Kakar P, Fox Z, et al. Cerebral microbleeds and recurrent stroke risk systematic review and Meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts［J］.Stroke,2013,44(4):995-1001.
［5］Lovelock CE, Cordonnier C, Nata H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage A systematic review of published and unpublished studies［J］.Stroke,2010,41:1222-1228.
［6］Fisher M, French S, Ji P, et al. Cerebral microbleeds in the elderly: a pathological analysis［J］.Stroke,2010,41(12):2782-2785.
［7］Hu YY, Dong XQ, Yu WH, et al. Change in plasma S100B level after acute spontaneous basal ganglia hemorrhage［J］.Shock,2010,33(2):134-140.
［8］Bouvier D. Interest of S100B protein blood level determination in severe or moderate head injury［J］.Ann Biol Clin (Paris),2013,71(2):145-150.
［9］Park IH, Yeon SI, Youn JH, et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells［J］.Mol Immunol,2004,40(16): 1203-1211.
［10］Bamford J, Sandercock P, Jones L, et al. The natural history of lacunar infarction: the oxforshire community stroke project［J］.Stroke,1987,18(3): 545-551.
［11］中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014［J］.中华神经科杂志,2015,48(4):246-257.
［12］桂军明, 谢道俊, 韦彪, 等. 黄芎抗栓胶囊治疗脑梗死急性期风痰瘀阻型伴胰岛素抵抗的临床研究［J］.北京中医药大学学报,2013,36(12):848-851.
［13］Scharf J, Brauherr E, Forsting M, et al. Significance of haemorrhagic lacunes on MRI in patients with hypertensive cerebrovascular disease and intracerebral haemorrhage［J］.Neuroradiology,1994, 36(7):504-508.
［14］Offenbacher H, Fazekas F, Schmidt R, et al. MR of cerebral abmormalities concomitant with primary intracerebral hematomas［J］.AJNR Am J Neuroradiol, 1996,17(3):573-578.
［15］Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting［J］.Brain,2007,130(Pt8):1988-2003.
［16］Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation［J］. Lancet Neurol,2009,8(2):165-174.
［17］Wardlaw J. Blood-brain barrier and cerebral small vessel disease［J］. J Neurol Sci,2010,299(1/2):66-71.
［18］Yao B, Zhang LN, Ai YH, et al. Serum S100beta is a better biomarker than neuron-specific enolase for sepsis-associated encephalopathy and determining its prognosis: a prospective and observational study［J］.Neurochem Res,2014, 39(7):1263-1269.
［19］Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death［J］.Diabetes,2013,62(6):2116-2121.
［20］Tsoporis JN, Mohammadzadeh F, Parker TG. S100B: a multifunctional role in cardiovascular pathophysiology［J］.Amino Acids,2011,41(4):843-847.
［21］熊爱莲, 李仲平. 疏肝解郁胶囊联合心理干预治疗脑卒中后抑郁［J］.长春中医药大学学报,2015,31(4):751-752.
［23］林棉, 杨楠, 王本国, 等. 活血化瘀治疗对脑微出血及脑梗死复发的影响［J］.新中医,2013,45(12):37-39.
［23］顾志燕, 王永. 血塞通联合奥扎格雷钠治疗急性脑梗死58例疗效观察［J］.中国药业,2014,23(4):18-19.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	秦文秀, 许军峰, 杨婷, 王坪霏. 丹参酮IIA治疗缺血性脑卒中后神经损伤的信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 705-713.
[3]	吴志勇, 刘兵荣, 李彬, 汤睿. 红细胞分布宽度对急性缺血性卒中静脉溶栓早期神经功能改善不良的预测作用[J]. 中国临床药理学与治疗学, 2023, 28(3): 307-314.
[4]	潘蓉蓉, 支英豪, 金永喜, 周夏慧. 茶黄素调节CaMKK2/AMPK信号通路对脑出血大鼠神经元凋亡和血脑屏障的影响[J]. 中国临床药理学与治疗学, 2022, 27(11): 1240-1246.
[5]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[6]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[7]	黄雅琴, 薛蓉. 急性脑血管病患者睡眠障碍的处理[J]. 中国临床药理学与治疗学, 2021, 26(5): 516-521.
[8]	夏春勇, 张作文, 贺小艳, 刘洁, 李小亚, 常秋红, 秦丽娟, 曹珍铭, 丁玲. 缺血性脑卒中患者CYP2C19基因多态性与个体化用药的相关性[J]. 中国临床药理学与治疗学, 2021, 26(3): 318-323.
[9]	严洁萍，章水均，张国兵，胡颖，罗丹，江红娟，李敏静. 丁苯酞对S-亚硝基化谷胱甘肽诱导脑微血管内皮细胞损伤的保护作用及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 517-522.
[10]	陈娟燕，宋水江，徐冬娟，徐琼，李鸿飞. 法舒地尔联合瑞舒伐他汀治疗血管性痴呆对认知功能、C-反应蛋白及氧化应激的影响[J]. 中国临床药理学与治疗学, 2018, 23(10): 1153-1158.
[11]	吴梦瑶赵洪庆王宇红. 抑郁症相关离子通道研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8): 949-954.
[12]	陈雁斌，邓珊珊. 醒脑静注射液对脑梗死缺氧诱导因子-1α表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(7): 821-824.
[13]	沈忱，李运曼，夏念，徐丹，韩丹，陈仕杰. Treg细胞抑制基质金属蛋白酶-9对类风湿性关节炎伴急性脑缺血损伤的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(7): 831-840.
[14]	刘振东，郑宁. 动脉粥样硬化性缺血性脑卒中患者血浆中TMAO与Lp-PLA2水平的相关性研究[J]. 中国临床药理学与治疗学, 2017, 22(6): 684-688.
[15]	马红岗，潘琴妹，朱斐斐，王亚仙，王庄. 白三烯B4、颈动脉斑块性质与进展性缺血性脑卒中相关性[J]. 中国临床药理学与治疗学, 2017, 22(6): 689-693.